Lineage has established GMP master and working cell banks and demonstrated AlloSCOPE 5D engineering at half-liter scale, combining 2D control with 3D efficiency. Management says this approach underpins scalable production of millions of vials and trillions of cells.

Roche and Genentech added 10 new GALE Phase 2a sites over the past nine months, bringing total locations to 17, and Lineage received its first $5 million development milestone under the collaboration. The program’s RMAT designation and increased site activations signal potential acceleration toward later-stage trials.

The diabetes islet cell research initiative passed its internal go/no-go milestone, moving toward large-scale bioreactor development. In spinal cord injury, the first chronic patient completed six-month follow-up without safety events, and Resonance secured funding from William Demant Invest to advance toward IND filing.